News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,423 Results
Type
Article (41540)
Company Profile (462)
Press Release (657421)
Section
Business (208381)
Career Advice (2001)
Deals (35936)
Drug Delivery (91)
Drug Development (83294)
Employer Resources (169)
FDA (16326)
Job Trends (15046)
News (352063)
Policy (32975)
Tag
Academia (2619)
Alliances (50571)
Alzheimer's disease (1262)
Approvals (16239)
Artificial intelligence (131)
Bankruptcy (361)
Best Places to Work (11682)
Biotechnology (346)
Breast cancer (113)
Cancer (980)
Cardiovascular disease (86)
Career advice (1670)
Cell therapy (223)
Clinical research (65733)
Collaboration (354)
Compensation (173)
COVID-19 (2582)
C-suite (86)
Data (922)
Diabetes (142)
Diagnostics (6165)
Earnings (85597)
Employer resources (147)
Events (112514)
Executive appointments (259)
FDA (16791)
Funding (313)
Gene therapy (168)
GLP-1 (598)
Government (4404)
Healthcare (18988)
Infectious disease (2660)
Inflammatory bowel disease (109)
Interviews (308)
IPO (16550)
Job creations (3694)
Job search strategy (1427)
Layoffs (436)
Legal (7923)
Lung cancer (160)
Manufacturing (162)
Medical device (13300)
Medtech (13305)
Mergers & acquisitions (19409)
Metabolic disorders (393)
Neuroscience (1518)
NextGen Class of 2024 (6732)
Non-profit (4535)
Northern California (1287)
Obesity (233)
Opinion (195)
Patents (97)
People (57511)
Pharmaceutical (87)
Phase I (20579)
Phase II (29006)
Phase III (21479)
Pipeline (257)
Postmarket research (2590)
Preclinical (8839)
Radiopharmaceuticals (250)
Rare diseases (202)
Real estate (5996)
Regulatory (21893)
Research institute (2402)
Resumes & cover letters (351)
Southern California (1158)
Startups (3745)
United States (12501)
Vaccines (556)
Weight loss (177)
Date
Today (252)
Last 7 days (950)
Last 30 days (3292)
Last 365 days (36648)
2024 (31918)
2023 (41015)
2022 (52279)
2021 (56772)
2020 (54928)
2019 (47424)
2018 (35702)
2017 (33031)
2016 (32352)
2015 (38402)
2014 (32188)
2013 (27111)
2012 (29225)
2011 (29865)
2010 (27993)
Location
Africa (731)
Arizona (195)
Asia (38429)
Australia (6385)
California (2962)
Canada (1205)
China (220)
Colorado (130)
Connecticut (136)
Europe (83796)
Florida (411)
Georgia (102)
Illinois (326)
Indiana (187)
Kansas (98)
Maryland (552)
Massachusetts (2452)
Michigan (146)
Minnesota (260)
New Jersey (871)
New York (879)
North Carolina (731)
Northern California (1287)
Ohio (131)
Pennsylvania (781)
South America (1105)
Southern California (1158)
Texas (414)
Washington State (342)
699,423 Results for "allos therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
November 7, 2024
·
11 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Biotech Beach
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate.
March 13, 2024
·
6 min read
Press Releases
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
October 30, 2024
·
7 min read
Press Releases
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
September 16, 2024
·
6 min read
Drug Development
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced new data from a subset of patients in an ongoing Phase 1 study of its lead program, P-BCMA-ALLO1.
April 8, 2024
·
9 min read
Genetown
Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen
Allos Pharma Inc., a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced that it has expanded its intellectual property rights with a new patent family.
September 18, 2023
·
2 min read
Press Releases
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 6, 2024
·
7 min read
Press Releases
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
September 27, 2024
·
6 min read
Biotech Bay
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
Allogene Therapeutics, Inc. announced the presentation of data from a comprehensive safety review of patients treated in the Phase 1 ALPHA/ALPHA2 trials with ALLO-501/501A at the 65th Annual Meeting of the American Society of Hematology in San Diego, CA.
December 9, 2023
·
8 min read
1 of 69,943
Next
